WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321

SHANGHAI, Feb. 23, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its strategic partner Immutep, a biotechnology comp...